KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares IssuedShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Idexx Laboratories (IDXX) Share-based Compensation (2016 - 2025)

Idexx Laboratories has reported Share-based Compensation over the past 17 years, most recently at $16.1 million for Q4 2025.

  • Quarterly results put Share-based Compensation at $16.1 million for Q4 2025, up 13.0% from a year ago — trailing twelve months through Dec 2025 was $60.0 million (changed 0.47% YoY), and the annual figure for FY2025 was $60.0 million, changed 0.47%.
  • Share-based Compensation for Q4 2025 was $16.1 million at Idexx Laboratories, up from $14.4 million in the prior quarter.
  • Over the last five years, Share-based Compensation for IDXX hit a ceiling of $16.1 million in Q4 2025 and a floor of $8.9 million in Q1 2021.
  • Median Share-based Compensation over the past 5 years was $14.3 million (2024), compared with a mean of $13.4 million.
  • Biggest five-year swings in Share-based Compensation: soared 36.71% in 2022 and later fell 9.33% in 2025.
  • Idexx Laboratories' Share-based Compensation stood at $9.7 million in 2021, then soared by 36.71% to $13.3 million in 2022, then rose by 14.64% to $15.2 million in 2023, then dropped by 6.34% to $14.3 million in 2024, then grew by 13.0% to $16.1 million in 2025.
  • The last three reported values for Share-based Compensation were $16.1 million (Q4 2025), $14.4 million (Q3 2025), and $14.9 million (Q2 2025) per Business Quant data.